Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland

References

• National Institute for Health and Care Excellence (NICE). Human growth hormone (somatropin) for the treatment of growth failure in children. Technology appraisal guidance [TA188]. 2010 [cited 2021 May 26]. Available from: https://www.nice.org.uk/guidance/ta188
   Google Scholar
• Lindsay R, Feldkamp M, Harris D, et al. Utah growth study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994;125(1):29–35. doi: 10.1016/s0022-3476(94)70117-2.
   PubMed Web of Science ®Google Scholar
• Thomas M, Massa G, Craen M, et al. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol. 2004;151(1):67–72. doi: 10.1530/eje.0.1510067.
   PubMed Web of Science ®Google Scholar
• Reh CS, Geffner ME. Somatotropin in the treatment of growth hormone deficiency and turner syndrome in pediatric patients: a review. Clin Pharmacol. 2010;2:111–122.
   PubMedGoogle Scholar
• Stagi S, Scalini P, Farello G, et al. Possible effects of an early diagnosis and treatment in patients with growth hormone deficiency: the state of art. Ital J Pediatr. 2017;43(1):81. doi: 10.1186/s13052-017-0402-8.
   PubMedGoogle Scholar
• Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–397. doi: 10.1159/000452150.
   PubMed Web of Science ®Google Scholar
• Ranke MB. Short and long-term effects of growth hormone in children and adolescents with GH deficiency. Front Endocrinol. 2021;12:720419. doi: 10.3389/fendo.2021.720419.
   PubMed Web of Science ®Google Scholar
• Foo J, Maghnie M, Colao A, et al. Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy. Clinicoecon Outcomes Res. 2019;11:525–537. doi: 10.2147/CEOR.S195265.
   PubMed Web of Science ®Google Scholar
• Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010 Jan;95(1):167–177. doi: 10.1210/jc.2009-0178.
   PubMed Web of Science ®Google Scholar
• Bell JJ, Lippe B, Romano AA, et al. National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries. Pediatr Endocrinol Rev. 2018;16(2):240–255.
   PubMed Web of Science ®Google Scholar
• Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab. 2022;107(12):3287–3301. doi: 10.1210/clinem/dgac517.
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Polak M, Backeljauw P, et al. Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet® IOS and ANSWER program. J Clin Endocrinol Metab. 2019;104(10):4730–4742. doi: 10.1210/jc.2019-00775.
   PubMed Web of Science ®Google Scholar
• Brod M, Alolga SL, Beck JF, et al. Understanding burden of illness for child growth hormone deficiency. Qual Life Res. 2017;26(7):1673–1686. doi: 10.1007/s11136-017-1529-1.
   PubMed Web of Science ®Google Scholar
• Brod M, Højbjerre L, Alolga SL, et al. Understanding treatment burden for children treated for growth hormone deficiency. Patient. 2017;10(5):653–666. doi: 10.1007/s40271-017-0237-9.
   PubMedGoogle Scholar
• Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther. 2008;30(2):307–316. doi: 10.1016/j.clinthera.2008.02.017.
   PubMed Web of Science ®Google Scholar
• Turner-Bowker DM, Yaworsky A, Palladino A, et al. Development and psychometric evaluation of the life interference questionnaire for growth hormone deficiency (LIQ-GHD) to assess growth hormone injection burden in children and adults. Patient. 2020;13(3):289–306. doi: 10.1007/s40271-019-00405-7.
   PubMedGoogle Scholar
• Gomez R, Ahmed SF, Maghnie M, et al. Treatment adherence to injectable treatments in pediatric growth hormone deficiency compared with injectable treatments in other chronic pediatric conditions: a systematic literature review. Front Endocrinol. 2022;13:795224. doi: 10.3389/fendo.2022.795224.
   PubMed Web of Science ®Google Scholar
• Acerini CL, Segal D, Criseno S, et al. Shared decision-making in growth hormone therapy-implications for patient care. Front Endocrinol. 2018;9:688. doi: 10.3389/fendo.2018.00688.
   PubMed Web of Science ®Google Scholar
• Acerini CL, Wac K, Bang P, et al. Optimizing patient management and adherence for children receiving growth hormone. Front Endocrinol. 2017;8:313. doi: 10.3389/fendo.2017.00313.
   PubMed Web of Science ®Google Scholar
• Mohseni S, Heydari Z, Qorbani M, et al. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. 2018;31(1):13–20. doi: 10.1515/jpem-2017-0157.
   PubMed Web of Science ®Google Scholar
• Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79(4):189–196. doi: 10.1159/000350251.
   PubMed Web of Science ®Google Scholar
• Aydın BK, Aycan Z, Sıklar Z, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract. 2014;20(1):46–51. doi: 10.4158/EP13194.OR.
   PubMed Web of Science ®Google Scholar
• Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011;6(1):e16223. doi: 10.1371/journal.pone.0016223.
   PubMed Web of Science ®Google Scholar
• Farfel A, Shalitin S, Morag N, et al. Long-term adherence to growth hormone therapy in a large health maintenance organization cohort. Growth Horm IGF Res. 2019;44:1–5. doi: 10.1016/j.ghir.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Maggio MC, Vergara B, Porcelli P, et al. Improvement of treatment adherence with growth hormone by easypod device: experience of an Italian centre. Ital J Pediatr. 2018;44(1):113. doi: 10.1186/s13052-018-0548-z.
   PubMedGoogle Scholar
• Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93(2):147–148. doi: 10.1136/adc.2006.114249.
   PubMed Web of Science ®Google Scholar
• Loftus J, Miller BS, Parzynski CS, et al. Association of daily growth hormone injection adherence and height among children with growth hormone deficiency. Endocr Pract. 2022;28(6):565–571. doi: 10.1016/j.eprac.2022.02.013.
   PubMed Web of Science ®Google Scholar
• Koledova E, Stoyanov G, Ovbude L, et al. Adherence and long-term growth outcomes: results from the easypod™ connect observational study (ECOS) in paediatric patients with growth disorders. Endocr Connect. 2018;7(8):914–923. doi: 10.1530/EC-18-0172.
   PubMed Web of Science ®Google Scholar
• de Arriba Munoz A, Muniz VC, Saez JJA, et al. Impact of adherence on growth response during the first 2 years of growth hormone treatment. Endocrine. 2021;72(2):513–523. doi: 10.1007/s12020-020-02560-6.
   PubMed Web of Science ®Google Scholar
• Rodríguez Arnao MD, Rodríguez Sánchez A, Díez López I, et al. Adherence and long-term outcomes of growth hormone therapy with easypod™ in pediatric subjects: Spanish ECOS study. Endocr Connect. 2019;8(9):1240–1249. doi: 10.1530/EC-19-0325.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Reimbursement review - somatrogon (Ngenla). Ottawa: CADTH; 2022.
   Google Scholar
• Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717–e2728. doi: 10.1210/clinem/dgac220.
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Carakushansky M, Galcheva S, et al. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. Journal of the Endocrine Society. 2022;6(10):bvac117. doi: 10.1210/jendso/bvac117.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Commo drug review - pharmaeconomic review report - somatropin (genotropin) for subcutaneous injection. Ottawa: CADTH; 2022.
   Google Scholar
• Saz-Parkinson Z, del Sol Granados Alonso M, Co JM. Study of adherence to recombinant growth hormone treatment of children with a GH deficiency: contributions to treatment control and economic impact. Public Health Technology Assessment Report IPEAmate Blan2013/70. Spanish HTA Agency; 2013.
   Google Scholar
• Scottish Medicines Consortium (SMC). somatropin for injection, 5mg/mL vial of powder and solvent for solution for subcutaneous injection and 3.3mg/mL and 6.7mg/mL penfill cartridge of solution for subcutaneous injection (OmnitropeÒ) No. (598/10). Scottish Medicines Consortium; 2010.
   Google Scholar
• Vorontsovaa M, Nagaevaa E, Naigovzinab N. Cost-effectiveness of growth hormone therapy in children in Russia. SPE Abstracts. 2018;89: P-P3-208.
   Google Scholar
• Howard SR, Butler GE. An analysis of the clinical and cost effectiveness of growth hormone replacement therapy before and during puberty: should we increase the dose? Horm Res Paediatr. 2013;79(2):75–82. doi: 10.1159/000346687.
   PubMed Web of Science ®Google Scholar
• Lee JM, Davis MM, Clark SJ, et al. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160(3):263–269. doi: 10.1001/archpedi.160.3.263.
   PubMedGoogle Scholar
• Christensen T, Fidler C, Bentley A, et al. The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden. J Med Econ. 2010;13(1):168–178. doi: 10.3111/13696991003652248.
   PubMedGoogle Scholar
• Joshi AV, Munro V, Russell MW. Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006;22(2):351–357. doi: 10.1185/030079906X80503.
   PubMed Web of Science ®Google Scholar
• Solem C, Smith C, Wiegand P, et al. PDB29 budget impact analysis of norditropin versus three leading market growth hormone therapies. Value Health. 2012;15(4):A175. doi: 10.1016/j.jval.2012.03.950.
   PubMed Web of Science ®Google Scholar
• Briggs AH, O’Brien BJ. The death of cost-minimization analysis? Health Econ. 2001;10(2):179–184. doi: 10.1002/hec.584.
   PubMed Web of Science ®Google Scholar
• Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Econ. 2013;22(1):22–34. doi: 10.1002/hec.1812.
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Ranke MB, Lindberg A, Board KI. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95(3):1229–1237. doi: 10.1210/jc.2009-1471.
   PubMed Web of Science ®Google Scholar
• Quigley CA, Child CJ, Zimmermann AG, et al. Mortality in children receiving growth hormone treatment of growth disorders: data from the genetics and neuroendocrinology of short stature international study. J Clin Endocrinol Metab. 2017;102(9):3195–3205. doi: 10.1210/jc.2017-00214.
   PubMed Web of Science ®Google Scholar
• Spandonaro F, Mancusi L. Valutazione di efficienza nella somministrazione dell’ormone della crescita (GH). Farmeconomia. Health economics and therapeutic pathways, 2013;14(1):7–17.
   Google Scholar
• Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14(42):1–209. iii–iv. doi: 10.3310/hta14420.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Correction to: consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy. 2022;20(5):781–782. doi: 10.1007/s40258-022-00743-y.
   PubMed Web of Science ®Google Scholar
• Cole TJ, Singhal A, Fewtrell MS, et al. Weight centile crossing in infancy: correlations between successive months show evidence of growth feedback and an infant-child growth transition. Am J Clin Nutr. 2016;104(4):1101–1109. doi: 10.3945/ajcn.116.139774.
   PubMed Web of Science ®Google Scholar
• Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Statist Med. 1998;17(4):407–429. doi: 10.1002/(SICI)1097-0258(19980228)17:4 < 407::AID-SIM742 > 3.0.CO;2-L.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230. doi: 10.1007/s10198-010-0224-8.
   PubMed Web of Science ®Google Scholar
• Evans M, Jensen HH, Bøgelund M, et al. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16(11):1357–1365. doi: 10.3111/13696998.2013.846262.
   PubMedGoogle Scholar
• Henry N, Jovanović J, Schlueter M, et al. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia a in Sweden. J Med Econ. 2018;21(4):318–325. doi: 10.1080/13696998.2017.1405816.
   PubMed Web of Science ®Google Scholar
• Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products–liraglutide and exenatide–for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–661. doi: 10.3111/13696998.2010.529377.
   PubMedGoogle Scholar
• Rajan N, Boye KS, Gibbs M, et al. Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg Issues. 2016;9:67–71. doi: 10.1016/j.vhri.2015.11.006.
   PubMedGoogle Scholar
• Ridderstråle M, Evans LM, Jensen HH, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes. 2016;14:13. doi: 10.1186/s12955-016-0411-0.
   PubMed Web of Science ®Google Scholar
• IMS Institute for Healthcare Informatics. IMS Health Ireland 2022. Market shares by SKU BrandUnit. Dublin, Ireland; 2022.
   Google Scholar
• HPRA. HPRA - Health Products Regulatory Authority; [cited 2023 Jan 16]. Available from: https://www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine/results?query=norditropin&field=
   Google Scholar
• Health Information and Quality Authority (HIQA). Guidelines for the economic evaluation of health technologies in Ireland; 2020 [cited 2022 Feb 12]. Available from: https://www.hiqa.ie/reports-and-publications/health-technology-assessment/guidelines-economic-evaluation-health
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Mehl A, Goh A, Gupta S. EE589 cost-effectiveness of once-daily somatropin from Sandoz versus once-weekly somatrogon for the treatment of growth hormone deficiency in children and adolescents. Value Health. 2022;25(12):S171. doi: 10.1016/j.jval.2022.09.828.
   PubMed Web of Science ®Google Scholar
• Bouillon R, Koledova E, Bezlepkina O, et al. Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab. 2004;89(10):4993–4998. doi: 10.1210/jc.2004-0054.
   PubMed Web of Science ®Google Scholar
• Health Service Executive - Primary Care Reimbursement Service. List of reimbursable items; 2022 Dec. Available from: https://www.hse.ie/eng/staff/pcrs/online-services/
   Google Scholar
• Human growth hormone (Somatropin) for treatment of adult growth hormone deficiency prescribing support information; [cited 2022 Feb 12]. Available from: https://www.cambridgeshireandpeterboroughccg.nhs.uk/easysiteweb/getresource.axd?assetid=18581&type=0&servicetype=1
   Google Scholar
• Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator’s choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere. 2022;6(12):e801. doi: 10.1097/HS9.0000000000000801.
   PubMed Web of Science ®Google Scholar
• Healthcare Pricing Office (HPO). Activity based funding (ABF) 2022 admitted patient price list. Indicative patient day case. K64B endocrine disorders, MINC; 2022 [cited 2022 Feb 15]. Available from: https://www.hpo.ie/abf/ABF2022AdmittedPatientPriceList.pdf
   Google Scholar
• Fola Care Prices. [cited 2022 Feb 12]. Available from: https://fola.care/prices/
   Google Scholar
• Affidea Prices. 2022; [cited 2022 Feb 12]. Available from: https://www.affidea.ie/prices/
   Google Scholar
• The GP Surgery Prices. [cited 2022 Feb 12]. Available from: https://www.thegpsurgery.co.uk/blood-test/endocrinology/
   Google Scholar